Premium
Bisphosphonates for delivering drugs to bone
Author(s) -
Sun Shuting,
Tao Jianguo,
Sedghizadeh Parish P.,
Cherian Philip,
Junka Adam F.,
Sodagar Esmat,
Xing Lianping,
Boeckman Robert K.,
Srinivasan Venkatesan,
Yao Zhenqiang,
Boyce Brendan F.,
Lipe Brea,
Neighbors Jeffrey D.,
Russell R. Graham G.,
McKenna Charles E.,
Ebetino Frank H.
Publication year - 2021
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15251
Subject(s) - bone infection , medicine , osteomyelitis , intensive care medicine , bone cancer , drug , antibiotics , pharmacology , cancer , surgery , biology , microbiology and biotechnology
Advances in the design of potential bone-selective drugs for the treatment of various bone-related diseases are creating exciting new directions for multiple unmet medical needs. For bone-related cancers, off-target/non-bone toxicities with current drugs represent a significant barrier to the quality of life of affected patients. For bone infections and osteomyelitis, bacterial biofilms on infected bones limit the efficacy of antibiotics because it is hard to access the bacteria with current approaches. Promising new experimental approaches to therapy, based on bone-targeting of drugs, have been used in animal models of these conditions and demonstrate improved efficacy and safety. The success of these drug-design strategies bodes well for the development of therapies with improved efficacy for the treatment of diseases affecting the skeleton. LINKED ARTICLES: This article is part of a themed issue on The molecular pharmacology of bone and cancer-related bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.